Fair Pay & Worker Respect

No specific, quantifiable data points for Pulse Biosciences, Inc. were found in the provided articles for any of the KPIs related to Fair Pay & Worker Respect. While CEO compensation for PLSE.US was stated as $5,864,450 in 2023

, the median employee compensation for the company was not provided, preventing the calculation of the CEO median pay ratio. General salary ranges and an employee compensation and benefits rating of 3.6/5 stars were mentioned , but these are not specific enough to map to the defined KPI thresholds for living wage coverage, pay equity, or worker engagement. The absence of reported regulatory actions or violations is not considered evidence of zero incidents, as per the scoring rules.

Fair Trade & Ethical Sourcing

No data relevant to Pulse Biosciences, Inc. (PLSE.US) for Fair Trade & Ethical Sourcing KPIs was found in the provided articles.

All articles explicitly state that they pertain to Unilever and do not contain information specific to PLSE.US.

Honest & Fair Business

Pulse Biosciences was required by the SEC to establish a confidential hotline for financial concerns related to accounting, internal controls, or auditing.

Following a board restructuring on November 3, 2017, three new independent directors were appointed. With a total of six board members, this results in 50% of the board being independent.

Kind to Animals

No quantitative data, regulatory actions, violations, fines, compliance issues, certifications, awards, recognitions, comparisons to industry benchmarks, or peer comparisons were found in the provided article content.

The article content is entirely placeholder text and does not contain any relevant data for any of the specified KPIs.

No War, No Weapons

Pulse Biosciences' core business is medical technology, specifically Nano-Pulse Stimulation (NPS) for applications in immuno-oncology, dermatology, general tissue treatment, and veterinary medicine, indicating no dual-use products developed or sold.

The company's Code of Business Conduct and Ethics prohibits personnel from bringing weapons onto company property or to sponsored events, and its business model implies no exposure to controversial weapons. For conflict minerals, 8 out of 15 product-specific supplier responses (53.3%) indicated their products are from sources certified as conflict-free. However, the Conflict Minerals Report has not been subject to an independent private sector audit. The company sent surveys to 22 suppliers, receiving 16 responses (73% response rate) for its annual conflict partner review. Pulse Biosciences uses the standard Conflict Minerals Reporting Template established by the RBA and GeSI for data collection and verification, and relies on cross-industry initiatives like the RMI's conflict-free smelter program, but its Conflict Minerals Report has not been subject to an independent private sector audit. The company conducted a country of origin inquiry and due diligence for 3TG minerals, but this is a single assessment without recurring reviews. Of the 15 product-specific supplier responses, nine stated that at least some 3TG minerals were sourced from Covered Countries, and six were uncertain of origin, indicating 60% of product-specific suppliers may have sourced from conflict regions.

Planet-Friendly Business

Pulse Biosciences reported combined Scope 1 and 2 GHG emissions of 558.4 tCO2e in 2022, with a projected decline to 335.4 tCO2e in 2023, representing a 39.9% annual reduction.

The company stated it was in material compliance with all applicable environmental laws and had not received notice of any actual or potential liability for environmental issues. In 2022, it reported zero environmental violation citations. In 2020 and 2021, 46% of waste from a warehouse clean-out was directed to recycling, with 54% going to landfill. The company used 22% renewable energy in 2022 and has a target of 30% for 2023. It collaborates with the Alberta Biodiversity Monitoring Institute by supplying geo-referenced seismic data to support their Human Footprint Monitoring Program, providing 600,000 linear kilometers of data. The company has used low-impact seismic techniques since 2005, including 'avoidance' cutting and careful remediation.

Safe & Smart Tech

Pulse Biosciences utilizes Arena to ensure compliance, which has facilitated the completion of state-level audits.

The company's Code of Business Conduct and Ethics applies globally to all personnel, emphasizing adherence to all applicable laws, regulations, and ethical standards. Additionally, the company has an FDA 510(k) clearance (K203299) for its CellFX System, indicating compliance with specific medical device regulations.

Zero Waste & Sustainable Products

The provided articles for Pulse Biosciences (PLSE.US) primarily focus on overall ESG scores and impact ratios. They explicitly state a lack of specific data for all relevant KPIs under the 'Zero Waste & Sustainable Products' value, including waste diversion rate, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, and supplier/customer waste education programs.

Information regarding B. Braun's sustainability initiatives is not explicitly attributed to Pulse Biosciences. Therefore, no KPIs can be scored based on the evidence provided.